These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 18291606)

  • 1. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration.
    Gedulin BR; Smith PA; Jodka CM; Chen K; Bhavsar S; Nielsen LL; Parkes DG; Young AA
    Int J Pharm; 2008 May; 356(1-2):231-8. PubMed ID: 18291606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
    Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes.
    Taylor K; Kim D; Nielsen LL; Aisporna M; Baron AD; Fineman MS
    Horm Metab Res; 2005 Oct; 37(10):627-32. PubMed ID: 16278786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
    Linnebjerg H; Kothare PA; Skrivanek Z; de la Peña A; Atkins M; Ernest CS; Trautmann ME
    Diabet Med; 2006 Mar; 23(3):240-5. PubMed ID: 16492205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, in vitro and in vivo correlation, and efficacy of exenatide microspheres in diabetic rats.
    Li X; Zhao Z; Li L; Zhou T; Lu W
    Drug Deliv; 2015 Jan; 22(1):86-93. PubMed ID: 24467493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures.
    Mack CM; Moore CX; Jodka CM; Bhavsar S; Wilson JK; Hoyt JA; Roan JL; Vu C; Laugero KD; Parkes DG; Young AA
    Int J Obes (Lond); 2006 Sep; 30(9):1332-40. PubMed ID: 16534527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
    Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
    J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db mice.
    Leinung MC; Grasso P
    Regul Pept; 2012 Nov; 179(1-3):33-8. PubMed ID: 22960403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exenatide: a novel incretin mimetic agent for treating type 2 diabetes mellitus.
    Lam S; See S
    Cardiol Rev; 2006; 14(4):205-11. PubMed ID: 16788334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes.
    Molina Vega M; Muñoz-Garach A; Tinahones FJ
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):207-217. PubMed ID: 29260924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo evaluation of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel.
    Yu L; Li K; Liu X; Chen C; Bao Y; Ci T; Chen Q; Ding J
    J Pharm Sci; 2013 Nov; 102(11):4140-9. PubMed ID: 24114868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats.
    Li XG; Li L; Zhou X; Chen Y; Ren YP; Zhou TY; Lu W
    Acta Pharmacol Sin; 2012 Nov; 33(11):1379-86. PubMed ID: 22659626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes.
    Fineman MS; Shen LZ; Taylor K; Kim DD; Baron AD
    Diabetes Metab Res Rev; 2004; 20(5):411-7. PubMed ID: 15343588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
    Sheffield CA; Kane MP; Busch RS
    Pharmacotherapy; 2007 Oct; 27(10):1449-55. PubMed ID: 17896900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.
    Chae SY; Jin CH; Shin HJ; Youn YS; Lee S; Lee KC
    Bioconjug Chem; 2008 Jan; 19(1):334-41. PubMed ID: 18078308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exenatide improves hypertension in a rat model of the metabolic syndrome.
    Laugero KD; Stonehouse AH; Guss S; Landry J; Vu C; Parkes DG
    Metab Syndr Relat Disord; 2009 Aug; 7(4):327-34. PubMed ID: 19320558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of low molecular weight protamine to enhance oral absorption of exenatide.
    Zhang L; Shi Y; Song Y; Sun X; Zhang X; Sun K; Li Y
    Int J Pharm; 2018 Aug; 547(1-2):265-273. PubMed ID: 29800739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes.
    Linnebjerg H; Park S; Kothare PA; Trautmann ME; Mace K; Fineman M; Wilding I; Nauck M; Horowitz M
    Regul Pept; 2008 Nov; 151(1-3):123-9. PubMed ID: 18675854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects.
    Blase E; Taylor K; Gao HY; Wintle M; Fineman M
    J Clin Pharmacol; 2005 May; 45(5):570-7. PubMed ID: 15831781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained-release study on Exenatide loaded into mesoporous silica nanoparticles: in vitro characterization and in vivo evaluation.
    Chen C; Zheng H; Xu J; Shi X; Li F; Wang X
    Daru; 2017 Sep; 25(1):20. PubMed ID: 28870261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.